Completion of first ultrasound date was higher in the re-abstraction database.
In total, the completeness in the follow-up date was high (~94.3%) while completeness of therapy start date and follow-up status was very high (> 97%).
An increase in dose was considered to have occurred if the most recent dose before the index date was higher than the second most recent dose before the index date.
The percentage of subjects with a screening mammogram within 2 years of the reference date was higher for invasive cases (71%) than for controls (58%) and cases were more likely to report a previous breast biopsy than controls.
Mean all-cause total health-care costs from the 180 days before the index date through the index date were highest among patients with CKD ($19,405) and anemia ($18,011) and lowest among those with asthma ($10,583) and osteoporosis ($11,438).
The average all-cause total health-care costs from the index date to 360 days after the index date were highest for patients with chronic kidney disease ($41,288) and anemia ($38,870).
All-cause total health-care costs during the time period from the index date through 360 days following the index date were highest among patients with COPD and CKD ($41,288) and patients with COPD and anemia ($38,870) (Table 3).
The crude CFR for all cases to date is high (CFR = 59.1%, interquartile range 32.5 77.8), but also varies substantially among the 15 countries.
In Caucasian populations, in Italy and Spain, the recommended doses in the phase I studies carried out to date are higher than those in the Japanese trials.
Unadjusted outcomes such as, proportion receiving any rehabilitation services in the year after index date and proportion who died in the year after index study date, were higher in the stroke cohort versus the control group (p-values <0.0001) (Table 1).
